3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Interventions
etrolizumab
5
Infliximab
4
Adalimumab
4
golimumab
3
Nivolumab
3
Specimen Handling
2
Colonoscopy
2
CT-P13
2
pembrolizumab
1
peficitinib
1
cabozantinib
1
Vitamin E
1
Sutures
1
Surgical Instruments
1
Ringer's Lactate
1
Proctectomy
1
Pneumococcal Vaccines
1
Platinum Compounds
1
Papillomavirus Vaccines
1
Narrow Band Imaging
1
NX-13
1
Methylprednisolone
1
Mesalamine
1
Medical Marijuana
1
Lysine Acetyltransferase 5
1
Loperamide
1
Iron-Dextran Complex
1
Ipilimumab
1
Injections
1
Indigo Carmine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Colitis, Ulcerative
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled